Please login to the form below

Not currently logged in
Email:
Password:

HER2-negative breast cancer

This page shows the latest HER2-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

The phase 3 OlympiA trial is investigating Lynparza versus placebo in the adjuvant setting for patients with inherited (germline) BRCA-mutated (gBRCAm), high-risk HER2-negative early breast cancer. ... Lynparza is already approved for the treatment of

Latest news

More from news
Approximately 1 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics